



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

(Rac)-Moxifloxacin-d₄

Cat. No.:	HY-66011BS
CAS No.:	2512220-27-6
Molecular Formula:	C ₂₁ H ₂₀ D ₄ FN ₃ O ₄
Molecular Weight:	405.46
Target:	Isotope-Labeled Compounds; Antibiotic; Bacterial
Pathway:	Others; Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

(Rac)-Moxifloxacin-d₄ ((Rac)-BAY 12-8039-d₄ (free base)) is deuterium labeled (Rac)-Moxifloxacin. (Rac)-Moxifloxacin ((Rac)-BAY 12-8039 free base) is the isoform of Moxifloxacin Hydrochloride (HY-66011), which is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia^{[1][2]}.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.
- [2]. Culley CM, et al. Moxifloxacin: clinical efficacy and safety. *Am J Health Syst Pharm*. 2001 Mar 1;58(5):379-88.
- [3]. Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. *Drugs*. 2000 Jan;59(1):115-39.
- [4]. Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against *Listeria monocytogenes*. *Antimicrob Agents Chemother*. 2008 May;52(5):1697-702.
- [5]. Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by *Stenotrophomonas maltophilia*. *Microbiol Immunol*. 2014 Feb;58(2):96-102.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA